AVXL — Anavex Life Sciences Share News
0.000.00%
Last trade - 00:00- $106.60m
- -$11.72m
U.S. STOCKS ON THE MOVE-ADMA Biologics, Nanobiotix, DraftKings
U.S. STOCKS ON THE MOVE-BWX, Generac, Cintas
U.S. STOCKS ON THE MOVE-Arm, On Holding, Sarepta
Brief: Anavex Life Sciences Provides Update On Regulatory Review In The EU For Blarcamesine To Treat Early Alzheimer’S Disease
Anavex withdraws EU filing for Alzheimer's drug, shares fall
Brief: Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results And Provides Business Update
Brief: Anavex Life Sciences Appoints Senior Vice President Global Head Of Neurology
Brief: Anavex Life Sciences Requests EMA To Re-Examine Blarcamesine For Alzheimer's
Brief: Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results
Brief: Anavex Life Sciences Announces Continued Long-Term Benefit From Oral Blarcamesine In Alzheimer’s Disease
U.S. RESEARCH ROUNDUP-Blackstone, Ford, Intel
U.S. STOCKS ON THE MOVE-AMD, Occidental Petroleum, Tesla
Anavex rises after schizophrenia drug meets main goal in study
U.S. STOCKS ON THE MOVE-Anavex Life Sciences, Oil companies, Yum! Brands
U.S. STOCKS ON THE MOVE-Anavex Life Sciences, oil companies, Yum Brands
U.S. STOCKS ON THE MOVE-Dick's Sporting Goods, Wix.com, NextDecade
Anavex Life Sciences climbs after Alzheimer's drug trial data
Brief: Anavex: Oral Blarcamesine Shows Cognitive Resilience Near Normal Aging in Alzheimer’s Trial
Anavex Life Sciences Corp reports results for the quarter ended June 30 - Earnings Summary